FINWIRES · TerminalLIVE
FINWIRES

CSL Cuts Fiscal 2026 Outlook, Flags $5 Billion of Additional Impairments; Shares Hit Nine-Year Low

By

-- CSL (ASX:CSL) lowered its guidance for fiscal 2026 and expects to recognize about $5 billion of additional non-cash, pre-tax impairments across fiscal 2026 and 2027 beyond those the company disclosed earlier this year, according to a Monday filing with the Australian bourse.

The biotechnology company now expects fiscal 2026 revenue of around $15.2 billion and net profit after tax adjusted to exclude amortization (NPATA) of around $3.1 billion, both on a constant-currency basis.

In February, it guided for 2% to 3% growth in revenue and 4% to 7% growth in NPATA.

The $5 billion of additional impairments include CSL Vifor intangible assets, including the product portfolio, as well as under-utilized property, plant and equipment, the company said.

CSL flagged a roughly $300 million fiscal 2026 revenue impact from its "normalization of channel inventory" for US immunoglobulin, a roughly $200 million hit from albumin in China, and an impact of about $150 million from other factors including the Middle East conflict.

"Our growth initiatives are working, but the financial benefits will take longer than previously anticipated to materialize," said interim CEO Gordon Naylor.

The company's shares tumbled 17% in recent Monday trade and earlier hit their lowest since December 2016.

Related Articles

Asia

Shenzhen LDROBOT Soars 103% in Hong Kong Trading Debut

Shenzhen LDROBOT's (HKG:1236) shares opened 102.9% above their initial public offering price in a stellar Hong Kong debut on Monday morning.The Chinese robotics company opened at HK$53.50 per share, well above the offer price of HK$26.36.

$HKG:1236
Asia

Concord Healthcare to Issue HK$68 Million Convertible Bonds to CSPC Pharma Unit

Concord Healthcare (HKG:2453) agreed to issue HK$68 million of convertible bonds to a unit of CSPC Pharmaceutical (HKG:1093), according to a Monday Hong Kong bourse filing.The oncology healthcare service provider said Dragon Merit will subscribe to the 2% convertible bonds due in April 2027.The bonds are convertible into as many as 40 million Hong Kong-listed shares at an initial conversion price of HK$1.70 per share, representing a premium of about 14.1% to the stock's last closing price.Net proceeds of about HK$63.1 million will mainly be used to repay loans and supplement working capital.Concord Healthcare said the investment is expected to deepen cooperation with CSPC Pharmaceutical in the oncology healthcare sector.

$HKG:1093$HKG:2453
Asia

Alterity Therapeutics Says Peer-Reviewed Study Validates its Approach to Multiple System Atrophy; Shares Fall 9%

Alterity Therapeutics (ASX:ATH) said findings of a study published in the NeuroImage journal support quantitative susceptibility mapping as an objective imaging biomarker to facilitate the earlier diagnosis of multiple system atrophy (MSA), according to a Monday filing with the Australian bourse.Alterity is advancing its ATH434 lead candidate into a phase three program for multiple system atrophy, a neurodegenerative disease that leads to the failure of the autonomic nervous system and impaired movement.The company said it used quantitative susceptibility mapping in a phase two trial in which ATH434 helped improve diagnostic accuracy and provided "objective evidence of target engagement."The peer-reviewed publication validates the company's approach and "reinforces the role of [quantitative susceptibility mapping] as a biomarker for iron-modulating therapies in MSA," Alterity CEO David Stamler said.The company's shares fell 9% in recent Monday trade.

$ASX:ATH